Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Multiple System Atrophy

    Current Location

    Search
    Multiple System Atrophy
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Geographic Atrophy Clinical Trials

    Top Spinal Muscular Atrophy Clinical Trials

    Top Multiple Sclerosis Clinical Trials

    Top Multiple Myeloma Clinical Trials

    Top Primary Progressive Multiple Sclerosis Clinical Trials

    26 Multiple Sclerosis Trials near Dallas, TX

    18 Multiple Sclerosis Trials near Houston, TX

    53 Multiple Sclerosis Trials near New York, NY

    164 Clinical Trials near Sacramento, CA

    Top Meningioma Clinical Trials

    Top Alopecia Clinical Trials

    Top Dysphagia Clinical Trials

    By Trial

    Risdiplam for Spinal Muscular Atrophy

    Long-term Follow-up with Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy · Info for Participants · Phase Phase 3 Clinical Trial 2025 | Power | Power

    Exergaming for Spinal Muscular Atrophy

    Autonomic Function Testing for Multiple Sclerosis

    Lifestyle and Supportive Care for Multiple Myeloma

    Cevostamab for Multiple Myeloma

    Hyalex System for Cartilage Damage

    Resistance Training vs Immobilization for Muscle Changes

    Radioimmunotherapy for Multiple Myeloma

    Belantamab Mafodotin for Multiple Myeloma

    Talquetamab for Multiple Myeloma

    Daratumumab for Smoldering Multiple Myeloma

    Related Searches

    Top Glioma Clinical Trials

    Top Nerve-pain Clinical Trials

    Top Her-2-positive-breast-cancer Clinical Trials

    Cu-SAR-bisPSMA for Prostate Cancer

    DVRd + Ciltacabtagene Autoleucel / ASCT for Multiple Myeloma

    Strength Training for Head and Neck Cancer Survivors

    Gastric Balloon for Obesity

    Durvalumab + BCG for Bladder Cancer

    Motivational Interviewing + Air Cleaners for COPD

    Dopamine for Pulmonary Diffusion and Capillary Blood Volume during Exercise. However, since the Layman Condition List is "Health" which is very broad, it is difficult to specify a specific condition for this trial

    Osimertinib for Early Stage Non-Small Cell Lung Cancer

    Amniotic Fluid Injection for Spinal Stenosis

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      30 Multiple System Atrophy Trials Near You

      Power is an online platform that helps thousands of Multiple System Atrophy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      GDNF Gene Therapy for Multiple System Atrophy

      Columbus, Ohio
      This trial is testing a new gene therapy for people with Multiple System Atrophy (MSA). The therapy uses a harmless virus to deliver a gene into the brain, which then produces a protein that helps protect brain cells. The goal is to see if this treatment is safe and if it can help slow down the progression of MSA.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:35 - 75

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Dementia, Psychosis, Cancer, Others
      Must Be Taking:Anti-parkinsonian

      9 Participants Needed

      Zoledronic Acid for Parkinson's Disease

      Columbus, Ohio
      This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Hip Fracture, Non-ambulatory, Kidney Dialysis, Others
      Must Not Be Taking:Bisphosphonates, SERMs, Denosumab

      2650 Participants Needed

      ONO-2808 for Multiple System Atrophy

      Columbus, Ohio
      This trial is testing a new drug called ONO-2808 in patients with Multiple System Atrophy (MSA). The study aims to see if the drug is safe, how it behaves in the body, and whether it can improve symptoms of MSA. Researchers are comparing three different doses of ONO-2808.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:30 - 80

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Neurological Diseases, Liver Diseases, Others

      92 Participants Needed

      Ampreloxetine for Multiple System Atrophy

      Cincinnati, Ohio
      This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Coronary Artery Disease, Others
      Must Not Be Taking:Antihypertensives, MAOIs, CYP1A2 Inhibitors

      102 Participants Needed

      TAK-341 for Multiple System Atrophy

      Cleveland, Ohio
      This trial tests TAK-341 in patients with multiple system atrophy (MSA). It aims to see if TAK-341 can improve or slow down MSA symptoms over several months. The study will measure changes in symptoms.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Confounding Diagnosis, Immunoglobulin G Therapy, Others

      159 Participants Needed

      Lu AF82422 for Multiple System Atrophy

      Cleveland, Ohio
      The main goal of this trial is to evaluate the efficacy and safety of Lu AF82422 for the treatment of participants with Multiple System Atrophy (MSA).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:40 - 75

      Key Eligibility Criteria

      Disqualifiers:Previous Lu AF82422, Other CNS Diseases, Others

      360 Participants Needed

      Sural Nerve Graft for Parkinson's Disease

      Lexington, Kentucky
      This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be enrolled, with 4 participants receiving the graft and 3 receiving a sham surgery. Eligible participants will be early in their diagnosis with a lower burden of symptoms. Participants will be followed initially for one year after surgery.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:40 - 75

      Key Eligibility Criteria

      Disqualifiers:Previous PD Surgery, Major Psychiatric Disorder, Others
      Must Not Be Taking:Neuroleptics, Anticoagulants

      7 Participants Needed

      TEV-56286 for Multiple System Atrophy

      Pittsburgh, Pennsylvania
      The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:30 - 75

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Pregnancy, Vulnerable Populations, Others

      200 Participants Needed

      Lu AF82422 for Multiple System Atrophy

      Pittsburgh, Pennsylvania
      This trial is testing a new drug called Lu AF82422 to see if it can slow down the progression of multiple system atrophy (MSA). MSA is a rare and worsening neurological condition, and current treatments may not be effective. The study will compare the new drug to determine its effectiveness.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:40 - 75

      Key Eligibility Criteria

      Disqualifiers:Serious Neurological Disorder, Others
      Must Not Be Taking:Anti-α-synuclein, Mesenchymal Stem

      64 Participants Needed

      ATH434 for Multiple System Atrophy

      Nashville, Tennessee
      This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:30 - 75

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      10 Participants Needed

      Accelerometer Monitoring for Neurogenic Orthostatic Hypotension

      Nashville, Tennessee
      The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing and walking; upright time) during 1 week of placebo (a pill with no active ingredients) and 1 week of their regular medication for orthostatic hypotension (midodrine or atomoxetine at their usual doses). Total upright time (i.e. tolerance to standing and walking) will be compared between placebo and active treatment to test the hypothesis that it can be used to assess the efficacy of the treatment for orthostatic hypotension and whether this outcome is superior to the assessment of symptoms using validated questionnaires.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Amyloidosis, Coronary Artery Disease, Others
      Must Be Taking:Midodrine, Atomoxetine

      29 Participants Needed

      YA-101 for Multiple System Atrophy

      Nashville, Tennessee
      This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Renal Impairment, Hepatic Impairment, Uncontrolled Diabetes, Others

      75 Participants Needed

      Trimethaphan for High Blood Pressure

      Nashville, Tennessee
      The purpose of this study is to learn more about the regulation of the veins of the abdomen by the autonomic (involuntary) nervous system, and how this may affect high blood pressure. Normally, the autonomic nervous system controls how much blood flows in the veins. In people with high blood pressure, however, the autonomic nervous system is changed. This change may affect the way blood flows in the veins of the abdomen which may play a role in their high blood pressure. About 32 participants will be screened for the study. The investigators estimate 16 will be eligible to participate in all of the study days.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Diabetes, Aortic Aneurysms, Others

      2 Participants Needed

      Abdominal Compression for Orthostatic Hypotension

      Nashville, Tennessee
      Compression garments have been shown to be effective in the treatment of orthostatic hypotension in autonomic failure patients. The purpose of this study is to determine the hemodynamic mechanisms by which abdominal compression (up to 40 mm Hg) improve the standing blood pressure and orthostatic tolerance in these patients, and to compare them with those of the standard of care midodrine. The investigators will test the hypothesis that abdominal compression will blunt the exaggerated fall in stroke volume and the increase in abdominal vascular volume during head up tilt.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cardiac, Renal, Hepatic, Others

      29 Participants Needed

      Automated Abdominal Binder for Orthostatic Hypotension

      Nashville, Tennessee
      This trial is testing a special belt that inflates to help people with low blood pressure when they stand up. It targets patients who have a condition that makes it hard for them to keep their blood pressure stable. The belt works by squeezing the abdomen to help keep blood flowing properly when standing.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Amyloidosis, Coronary Artery Disease, Others
      Must Not Be Taking:Anticoagulants

      31 Participants Needed

      Midodrine vs Abdominal Compression for Orthostatic Hypotension

      Nashville, Tennessee
      The purpose of this study is to learn more about the effects of abdominal compression and the medication midodrine, two interventions used for the treatment of orthostatic hypotension (low blood pressure on standing), on hemodynamic markers of cardiovascular risk. The study will be conducted at the Vanderbilt University Medical Center and consists of a screening and 2 testing days, one with abdominal compression and one with midodrine. The total length of the study will be about 5 days.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Supine Hypertension, Bedridden, Others

      31 Participants Needed

      Midodrine + Droxidopa for Autonomic Failure

      Nashville, Tennessee
      The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients with autonomic failure. The study will be conducted at Vanderbilt University Medical Center, and consists of 2 parts: a screening and 2 testing days. The total length of the study will be about 5 days. About 34 participants will be screened for the study.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Hypertension, Pregnancy, Others

      34 Participants Needed

      Heating Pad for High Blood Pressure

      Nashville, Tennessee
      Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension). Exposure to heat, such as in hot environments, often worsens their orthostatic hypotension. The causes of this are not fully understood. The purpose of this study is to evaluate whether applying local heat over the abdomen of patients with autonomic failure and supine hypertension during the night would decrease their nocturnal high blood pressure while lying down. This will help us better understand the mechanisms underlying this phenomenon, and may be of use in the treatment of supine hypertension.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cardiac, Renal, Hepatic, Others

      20 Participants Needed

      CPAP for Supine Hypertension

      Nashville, Tennessee
      This study aims to learn about the effects of continuous positive airway pressure (CPAP) on people with autonomic failure and high blood pressure when lying down (supine hypertension) to determine if it can be used to treat their high blood pressure during the night. CPAP (a widely used treatment for sleep apnea) involves using a machine that blows air into a tube connected to a mask covering the nose, or nose and mouth, to apply a low air pressure in the airways. The study includes 3-5 days spent in the Vanderbilt Clinical Research Center (CRC): at least one day of screening tests, followed by up to 3 study days. Subjects may be able to participate in daytime and/or overnight studies. The Daytime study consists of 2 study days: one with active CPAP and one with sham CPAP applied for up to 2 hours. The Overnight study consists of 3 study nights: one with active CPAP, one with sham CPAP, both applied for up to 9 hours and one night sleeping with the bed tilted head-up.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Recent Facial Trauma, Bedridden, Smokers, Others

      59 Participants Needed

      CPAP for Supine Hypertension

      Nashville, Tennessee
      Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Coronary Artery Disease, Others

      12 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Multiple System Atrophy Trial

      [18F]FDOPA Imaging for Parkinson's Disease

      Nashville, Tennessee
      Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and/or glia. The anatomical location of alpha-synuclein inclusions (Lewy Bodies) and the pattern of progressive neuronal death (e.g. caudal to rostral brainstem) give rise to distinct neurological phenotypes, including Parkinson's disease (PD), Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB). Common to these disorders are the involvement of the central and peripheral autonomic nervous system, where Pure Autonomic Failure (PAF) is thought (a) to be restricted to the peripheral autonomic system, and (b) a clinical risk factor for the development of a central synucleinopathy, and (c) an ideal model to assess biomarkers that predict phenoconversion to PD, MSA, or DLB. Such biomarkers would aid in clinical trial inclusion criteria to ensure assessments of disease- modifying strategies to, delay, or halt, the neurodegenerative process. One of these biomarkers may be related to the neurotransmitter dopamine (DA) and related changes in the substantia nigra (SN) and brainstem. \[18F\]F-DOPA is a radiolabeled substrate for aromatic amino acid decarboxylase (AAADC), an enzyme involved in the production of dopamine. Use of this radiolabeled substrate in positron emission tomography (PET) may provide insight to changes in monoamine production and how they relate to specific phenoconversions in PAF patients. Overall, this study aims to identify changes in dopamine production in key regions including the SN, locus coeruleus, and brainstem to distinguish between patients with PD, MSA, and DLB, which may provide vital information to predict conversion from peripheral to central nervous system disease.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Bioimplants, Pregnancy, Minors, Mental Disability, Others

      40 Participants Needed

      Palliative Care for Parkinson's Disease

      Rochester, New York
      The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Metastatic Cancer, Receiving Palliative Care, Others

      710 Participants Needed

      UB-312 Vaccine for Parkinson's & Multiple System Atrophy

      New York, New York
      This trial tests a new vaccine called UB-312, which aims to help patients with MSA and PD by teaching their immune systems to attack harmful brain proteins.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:40 - 75

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      8 Participants Needed

      Stem Cell Therapy for Neurological Disorders

      Westport, Connecticut
      This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Medically Unstable, Others

      500 Participants Needed

      Mesenchymal Stem Cell Therapy for Multiple System Atrophy

      Rochester, Minnesota
      The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA). Funding Source - FDA OOPD.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:30 - 80

      Key Eligibility Criteria

      Disqualifiers:Cancer, Dementia, Heart Failure, Others
      Must Not Be Taking:Neuroleptics, Anticholinergics, Others

      30 Participants Needed

      Stem Cell Therapy for Multiple System Atrophy

      Rochester, Minnesota
      This trial uses stem cells from a patient's own fat, injected into the spinal fluid, to treat early-stage Multiple System Atrophy (MSA). The goal is to slow down the disease by supporting and protecting nerve cells.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:30 - 70

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cancer, Autoimmune, Diabetes, Others
      Must Not Be Taking:Anticoagulants, Anti-Parkinsonian

      76 Participants Needed

      Foralumab Nasal for Multiple System Atrophy

      Boston, Massachusetts
      A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:30 - 85

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Claustrophobia, Cognitive Impairment, Others
      Must Be Taking:Dopaminergic Treatment

      5 Participants Needed

      PET Imaging for Parkinson's Disease

      Charlestown, Massachusetts
      The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: 1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of \[11C\]SY08 in healthy individuals An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Schizophrenia, Stroke, Others
      Must Not Be Taking:Anticoagulants

      40 Participants Needed

      Regulatory T Cells for ALS

      Wichita, Kansas
      An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Infection, Hypertension, Cardiology, Others
      Must Be Taking:Riluzole, Edaravone

      12 Participants Needed

      TEV-56286 for Multiple System Atrophy

      Spokane, Washington
      The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Detention, Others
      Must Not Be Taking:Prohibited Medications

      200 Participants Needed

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Multiple System Atrophy clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Multiple System Atrophy clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Multiple System Atrophy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Multiple System Atrophy is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Multiple System Atrophy medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Multiple System Atrophy clinical trials?

      Most recently, we added TEV-56286 for Multiple System Atrophy, Foralumab Nasal for Multiple System Atrophy and YA-101 for Multiple System Atrophy to the Power online platform.